ESMO 2017: Updated Data on Atezolizumab Plus Bevacizumab in Metastatic Renal Cell Carcinoma
At the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid, Thomas Powles, MRCP, MD, of Bart’s Cancer Institute, London, presented updated data on the phase II IMmotion150 trial, which confirmed the activity of atezolizumab plus bevacizumab in patients with metastatic renal cell carcinoma (Abstract LBA39). In the ongoing phase III IMmotion 151 trial, the clinical benefit of co-blockade of vascular endothelial growth factor with bevacizumab and programmed cell death ligand 1 (PD-L1) with atezolizumab versus sunitinib will be explored further.
A total of 305 patients with treatment-naive metastatic renal cell carcinoma were randomized to receive atezolizumab plus bevacizumab, atezolizumab alone, or sunitinib. Results remained consistent after a median follow-up of 25.7 months, suggesting a clinically meaningful benefit with the combination of atezolizumab and bevacizumab compared with sunitinib in patients with PD-L1–positive disease. The investigator-assessed progression-free survival hazard ratio for the combination therapy compared with sunitinib was 0.78 in the intent-to-treat population and 0.47 in the PD-L1–positive group.
Adverse events were comparable with the known safety profile of each medication, and the frequency of adverse events in all three arms were similar. The investigators noted that patients treated with atezoliumab tended to report less symptom severity and interference in daily function than those treated with sunitinib.